Speaker

Dr. Kam Tong Leung received his PhD degree and postdoctoral training from the Department of Paediatrics, The Chinese University of Hong Kong, and thereafter commenced his academic career in the same unit. He is currently leading a young but ambitious research team under the Hong Kong Hub of Paediatric Excellence (HK HOPE), with his lab operating in the Hong Kong Children’s Hospital. His research portfolio spans basic, translational and clinical hematology, with a particular focus on drug development for blood cancers. He has published 60+ papers in leading journals in the field of hematology, including Blood, Blood Cancer Discovery, Blood Advances, Leukemia and Haematologica, and has obtained 20+ research grants in the capacity of principal investigator, including external competitive fundings from the Hong Kong SAR Government. Dr. Leung’s research has also reached national and international scale, as exemplified by his award-winning collaborative studies with world-renowned oncology centers. He also holds several patents, is active in knowledge transfer activities, and has been the founder of “Homing Therapeutics” pursuing business in cell therapies. Beyond the academia, he is currently serving the Hospital Authority and Department of Health for reviewing clinical trials and manufacturers licensing of advanced therapy products.

Dr. Li Bin is a renowned immunologist serving as Deputy Director for Research at the Shanghai Institute of Immunology and a Distinguished Professor at Shanghai Jiao Tong University. Recognized as a National Science Fund for Distinguished Young Scholar (2015), Shanghai Leading Talent, and Outstanding Academic Leader, he has held leadership roles including Vice President of the Shanghai Overseas Returned Scholars Association and Chair of its Biopharma Chapter. With over 100 corresponding-author publications in top journals (e.g., Immunity, Nature Immunology) on FOXP3+ Treg research, he has led multiple national/international grants (NSFC Key Projects, Sino-US/Poland collaborations). His industry engagements include Founder/Science Committee Chair of Prometheus Biosciences (2018-2024), Huawei Health Cloud Advisor (2024), and executive roles in academic societies (e.g., Vice President of PENN Medicine China Club, Standing Committee Member of the Chinese Society for Cell Biology).

Prof. Chi-kong LI currently is Research Professor at Department of Paediatrics of The Chinese University of Hong Kong, and honorary consultant at Hong Kong Children’s Hospital. Dr. Li is specialized in paediatric haematology, oncology, stem cell transplantation and cellular therapy. He was the past Continental President of Asia of International Society of Pediatric Oncology. His main interest is in childhood leukaemia, palliative care and bioethics. He has published over 400 peer-reviewed papers.

David Li, Ph.D. in Pharmaceutical Sciences, serves as Vice President of the Innovative Institute of Basic Medical Sciences of Zhejiang University. His primary research and translational work focus on the field of synthetic biology. He has led or served as a key contributor in completing eight provincial/ministerial-level research projects and over ten industry-sponsored projects, resulting in more than ten provincially or ministerially recognized scientific achievements. With over 20 published scientific papers and two provincial/ministerial-level science and technology awards, he has extensive practical experience in technology transfer, industrial application of research, industrial strategic planning, and project investment. He has spearheaded multiple projects from inception to commercialization, successfully guiding them through to market launch.

George Li , Founder and Managing Partner of Proxima Investment, possesses nearly 20 years of experience in management, consulting, entrepreneurship, and investment within the healthcare sector. He serves as a committee member of the Innovation and Entrepreneurship Committee under the Overseas Chinese Affairs Office of the State Council, is recognized as an Innovation and Entrepreneurship Talent by the Ministry of Science and Technology, and acts as a judge for the Chunhui Cup Entrepreneurship Competition under the Ministry of Education.

He holds a Bachelor’s degree from Zhejiang University and an MBA from Hult International Business School. Previously, he worked at Huawei Technologies’ R&D Testing Department and co-founded BioHermes, a leading company in the diagnostic reagents niche in China. In 2008, he established BioBridge International, providing comprehensive services to healthcare innovation companies—from startup guidance and production system development to regulatory filing support.

Jinghua Li is an Associate Professor at the Faculty of Health Sciences, University of Macau. Her research focus on developing mathematical and statistical models to assess the epidemiological impact and cost-effectiveness of health interventions for infectious diseases. She has received the First Prize in the Educational Achievement Award from Guangdong Province Society for Academic Degrees and Graduate Education (as the first completer) and led a Guangdong Provincial Graduate Demonstration Course. She has served as principal investigator on projects funded by the National Natural Science Foundation of China, the Guangdong Natural Science Foundation, and the China Medical Board. She has published over 100 SCI/SSCI papers in journals such as The Lancet Regional Health–Western Pacific and eClinicalMedicine, with an H-index of 24. The dynamic intervention assessment tools she developed have been widely applied in both domestic and international cities. She has served as a council member of the China Health Policy and Management Society, is an active member of the Public Health and Preventive Medicine Branch of the China International Exchange and Promotive Association for Medical and Health Care, and is a recipient of the Early Career Award from the International Society of Behavioral Medicine.

Having worked in domestic and international enterprises producing antibiotics, blood products, pharmaceutical excipients, in vitro diagnostic reagents, and monoclonal antibody (mAb) drugs, he possesses over 30 years of experience in drug R&D, registration, production, and quality management. Currently serving as the ​Quality/Business Head​ of ​3SBio Inc.​, ​Vice Chairperson​ of the ​Biochemical Drugs Professional Committee​ of the ​Shanghai Pharmaceutical Association, and ​Council Member​ of the ​Shanghai Association for Quality​.

Dr. Xiang Li has nearly 30 years of experience in drug development and management, spanning the development of multiple drug modalities, including small molecules, antibodies, cell therapies, and targeted nuclear medicines. He previously worked at Boehringer Ingelheim’s US R&D center for over 21 years, focusing on the discovery of innovative drugs for immune, inflammatory, and metabolic diseases. He also worked at BioDuro-Sundia for six years, where, as President of the Drug Discovery Division, he was responsible for global business across chemistry, biology, pharmacology, oncology, biomacromolecules, and DMPK. He possesses a multifaceted international perspective and extensive experience leading multiple departments and centers. He holds a bachelor’s degree from the University of Science and Technology of China, a doctorate from the University of Oxford, and a postdoctoral fellowship at the Scripps Research Institute.

MD/PhD, Psychiatrist/Professor, Director of the Brain Center of the Second Affiliated Hospital of Zhejiang University School of Medicine. He is also the director of the Institute of Neuroscience of Zhejiang University, Chairman of the School of Medicine Council and Vice President of Zhejiang University. Graduated from the former First Military Medical University, Prof. Li received his bachelor’s and a doctoral degree in medicine. Previously, he served as Assistant Dean of Zhejiang University School of Medicine, Vice President of the Second Affiliated Hospital, Executive Dean of Zhejiang University School of Medicine, etc. Prof. Li has been engaged in teaching, scientific research and clinical work of mental diseases for a long time, focusing on understanding the circuit and molecular mechanisms underlying the emotions and related disorders, in identifying targets to develop therapeutic strategies for treating psychiatric disorders such as anxiety and depression disorders. He is the chief scientist of the Major Project of the National Natural Science Foundation “Mechanisms and Clinical Translation of Anxiety Disorder” and the Major Project of the Ministry of Science and Technology “Research on the Neural Circuit Mechanism of Fear Emotion”. Representative papers have been published in Cell, Nature Medicine, Nature Neuroscience, Neuron, Biological Psychiatry, etc. He also obtained a number of invention patents such as diagnostic kit for depression. Prof. Li has received the National Distinguished Youth Fund. His numerous honors include the First Prize of the Chinese Medical Science and Technology, the Tan Jiazhen Life Scientific Innovation Award, the Wu-Yang Award, and the Chinese Society for Neuroscience-CST Outstanding Neuroscientist Award.

Dr. You Li has more than 15 years of experience in product development and regulatory strategy for pharmaceuticals and medical devices. He currently serves as Founder and President of BioInsight. Dr. Li is also a board member and the past president of the Chinese Biopharmaceutical Association (CBA).Previously, Dr. Li held various leadership roles in pharmaceutical and medical device companies, as well as a regulatory agency. These positions include: Vice President, Program Executive and Clinical Strategy at EQRx (acquired by NASDAQ: RVMD in 2023); Vice President, Head of Regulatory Strategy at Thrive (acquired by NASDAQ: EXAS in 2021); Senior Lead Reviewer at the US FDA. Dr. Li received his PhD in Human Genetics from the University of Pittsburgh and dual Bachelor’s Degrees in Biology and Computer Science from Zhejiang University.